However, K. Ding, and colleagues (40) demonstrated through scRNA-seq and ATAC-seq profiling of 50 breast cancer organoid lines prior to drug screening that HER2+/ER- subclones can selectively expand during culture. This evidence concerns the gene ERBB2 and breast cancer.